Brief: Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis
20/08/2026 13:03
BRIEF-Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis Rein Therapeutics Inc RNTX.O:
REIN THERAPEUTICS RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR LTI-03 IN IDIOPATHIC PULMONARY FIBROSIS
REIN THERAPEUTICS - ENROLLING PATIENTS IN PHASE 2 RENEW TRIAL FOR LTI-03; INTERIM DATA EXPECTED H2 2026
Source text: ID:nGNX7GZ4ZK
Further company coverage: RNTX.O
Recent news on Rein Therapeutics
See all newsBrief: Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis
Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Rein Therapeutics Q2 net loss narrows on lower R&D spending
Rein Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering